Insmed
Commercializes rare pulmonary disease medicines while developing pulmonary, antibody and gene therapies.
$118.65
After-hours close+0.15 (+0.13%)
At close$118.50(−2.38%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 118.59%Insiders 0.71%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 216.75M · Float 198.42M · 91.5% free float
Institutions13F, as of Jun 30, 2026
715 holders · 257.05M shares · 115 new positions · 359 increased · 239 reduced · 124 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 16.14M | 7.45% | +2.98M | Aug 13, 2026 |
| BlackRock, Inc. | 15.81M | 7.29% | −870.2K | Aug 7, 2026 |
| JPMorgan Chase & Co | 10.43M | 4.81% | −13.72M | Aug 12, 2026 |
| Vanguard Portfolio Management LLC | 10.41M | 4.80% | +36.2K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 9.79M | 4.52% | +148.7K | Aug 13, 2026 |
| Baker Bros. Advisors LP | 8.80M | 4.06% | +1.38M | Aug 14, 2026 |
| Capital International Investors | 8.24M | 3.80% | +2.64M | Aug 12, 2026 |
| Darwin Global Management, Ltd. | 6.43M | 2.97% | −10.37M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| JPMorgan Chase & Co. | 10.80% | 23.01M | 13G | Sep 4, 2025 ↗ |
| Darwin Global Management, Ltd. | 7.80% | 16.81M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 6.60% | 14.12M | 13G | Jan 21, 2026 ↗ |
| FMR LLC | 6.10% | 13.15M | 13G | May 6, 2026 ↗ |
| Vanguard Capital Management | 5.34% | 11.51M | 13G | Apr 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| William Lewis | director, officer: Chair and CEO | 493.0K | 0.23% | Jul 24, 2026 |
| Melvin Md Sharoky | director | 246.1K | 0.11% | Aug 19, 2026 |
| David R. Brennan | director | 124.2K | 0.06% | May 15, 2026 |
| Roger Adsett | officer: Chief Operating Officer | 98.7K | 0.05% | Aug 12, 2026 |
| David W. J. Mcgirr | director | 97.7K | 0.05% | Feb 11, 2026 |
| Clarissa Desjardins | director | 73.3K | 0.03% | May 15, 2026 |
| Sara Bonstein | officer: Chief Financial Officer | 69.1K | 0.03% | Jun 5, 2026 |
| Carol Schafer | director | 66.6K | 0.03% | May 15, 2026 |
| Elizabeth M. Anderson | director | 62.0K | 0.03% | May 15, 2026 |
| Martina M.D. Flammer | officer: Chief Medical Officer | 60.5K | 0.03% | Aug 7, 2026 |
2 ten-percent owners hold 3.12M shares by Form 4, outside the officers-and-directors figure above · 26 people have not refiled in the last 18 months (1.34M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 17, 2026 | Melvin Md Sharokydirector | Sale | 5,000 | $127.53 | 0 |
| Aug 10, 2026 | Roger Adsettofficer: Chief Operating Officer | Sale | 239,850 | $133.27 | 98,744 |
| Aug 6, 2026 | Martina M.D. Flammerofficer: Chief Medical Officer | Sale · 2 lots | 27,173 | $128.61 | 60,486 |
| Jul 23, 2026 | William Lewisdirector, officer: Chair and CEO | Sale · 2 lots | 10,700 | $106.06 | 259,058 |
| Jul 9, 2026 | William Lewisdirector, officer: Chair and CEO | Sale · 3 lots | 10,699 | $117.40 | 259,058 |
| Jul 6, 2026 | Martina M.D. Flammerofficer: Chief Medical Officer | Sale · 2 lots | 12,302 | $109.98 | 60,486 |
| Jun 25, 2026 | William Lewisdirector, officer: Chair and CEO | Sale · 5 lots | 21,398 | $103.32 | 258,917 |
| Jun 22, 2026 | Michael Alexander Smithofficer: Chief Legal Officer | Sale | 1,806 | $95.82 | 37,648 |
| Jun 8, 2026 | William Lewisdirector, officer: Chair and CEO | Sale | 6,515 | $94.03 | 258,917 |
| Jun 5, 2026 | Martina M.D. Flammerofficer: Chief Medical Officer | Sale | 1,858 | $103.78 | 60,486 |
CongressHouse and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Josh Gottheimer · NJ05 | Sale | $1,001 – $15,000 | Joint | Jun 10, 2026 | Jul 8, 2026 ↗ |